Peripheral T-Cell Lymphomas (PTCL)-Pipeline Review, H2 2016

Peripheral T-Cell Lymphomas (PTCL)-Pipeline Review, H2 2016

  • Products Id :- GMDHC8436IDB
  • |
  • Pages: 246
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Peripheral T-Cell Lymphomas (PTCL)-Pipeline Review, H2 2016


Global Markets Direct's, 'Peripheral T-Cell Lymphomas (PTCL)-Pipeline Review, H2 2016', provides an overview of the Peripheral T-Cell Lymphomas (PTCL) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peripheral T-Cell Lymphomas (PTCL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral T-Cell Lymphomas (PTCL) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the global therapeutic landscape of Peripheral T-Cell Lymphomas (PTCL)

The report reviews pipeline therapeutics for Peripheral T-Cell Lymphomas (PTCL) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Peripheral T-Cell Lymphomas (PTCL) therapeutics and enlists all their major and minor projects

The report assesses Peripheral T-Cell Lymphomas (PTCL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Peripheral T-Cell Lymphomas (PTCL)

Reasons to Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Peripheral T-Cell Lymphomas (PTCL)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Peripheral T-Cell Lymphomas (PTCL) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Peripheral T-Cell Lymphomas (PTCL) Overview 10

Therapeutics Development 11

Pipeline Products for Peripheral T-Cell Lymphomas (PTCL)-Overview 11

Peripheral T-Cell Lymphomas (PTCL)-Therapeutics under Development by Companies 12

Peripheral T-Cell Lymphomas (PTCL)-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Peripheral T-Cell Lymphomas (PTCL)-Products under Development by Companies 17

Peripheral T-Cell Lymphomas (PTCL)-Companies Involved in Therapeutics Development 20

AB Science SA 20

Affimed GmbH 21

arGEN-X BV 22

Bayer AG 23

Boehringer Ingelheim GmbH 24

Celgene Corporation 25

CerRx, Inc. 26

Chipscreen Biosciences Ltd 27

CSPC Pharmaceutical Group Limited 28

Eisai Co., Ltd. 29

Genosco 30

Incyte Corporation 31

Japan Tobacco Inc. 32

Johnson & Johnson 33

Mundipharma International Ltd 34

Ono Pharmaceutical Co., Ltd. 35

Onxeo SA 36

Pfizer Inc. 37

Pharma Mar, S.A. 38

Portola Pharmaceuticals, Inc. 39

Rhizen Pharmaceuticals S.A. 40

Seattle Genetics, Inc. 41

Solasia Pharma K.K. 42

Spectrum Pharmaceuticals, Inc. 43

Peripheral T-Cell Lymphomas (PTCL)-Therapeutics Assessment 44

Assessment by Monotherapy Products 44

Assessment by Target 45

Assessment by Mechanism of Action 48

Assessment by Route of Administration 51

Assessment by Molecule Type 53

Drug Profiles 55

AFM-13-Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

ARGX-110-Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

belinostat-Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

brentuximab vedotin-Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

Cellular Immunotherapy to Target CD7 for Relapsed and Refractory Leukemia and Lymphoma-Drug Profile 96

Product Description 96

Mechanism Of Action 96

R&D Progress 96

cerdulatinib-Drug Profile 97

Product Description 97

Mechanism Of Action 97

R&D Progress 97

copanlisib hydrochloride-Drug Profile 101

Product Description 101

Mechanism Of Action 101

R&D Progress 101

darinaparsin-Drug Profile 105

Product Description 105

Mechanism Of Action 105

R&D Progress 105

denileukin diftitox-Drug Profile 108

Product Description 108

Mechanism Of Action 108

R&D Progress 108

enasidenib-Drug Profile 110

Product Description 110

Mechanism Of Action 110

R&D Progress 110

fenretinide-Drug Profile 116

Product Description 116

Mechanism Of Action 116

R&D Progress 116

forodesine hydrochloride-Drug Profile 118

Product Description 118

Mechanism Of Action 118

R&D Progress 118

ICG-122-Drug Profile 120

Product Description 120

Mechanism Of Action 120

R&D Progress 120

lenalidomide-Drug Profile 121

Product Description 121

Mechanism Of Action 121

R&D Progress 121

masitinib-Drug Profile 135

Product Description 135

Mechanism Of Action 135

R&D Progress 135

MEDI-570-Drug Profile 149

Product Description 149

Mechanism Of Action 149

R&D Progress 149

mitoxantrone hydrochloride-Drug Profile 150

Product Description 150

Mechanism Of Action 150

R&D Progress 150

nivolumab-Drug Profile 152

Product Description 152

Mechanism Of Action 152

R&D Progress 152

NL-101-Drug Profile 180

Product Description 180

Mechanism Of Action 180

R&D Progress 180

plitidepsin-Drug Profile 182

Product Description 182

Mechanism Of Action 182

R&D Progress 182

pralatrexate-Drug Profile 186

Product Description 186

Mechanism Of Action 186

R&D Progress 186

romidepsin-Drug Profile 192

Product Description 192

Mechanism Of Action 192

R&D Progress 192

RP-6530-Drug Profile 195

Product Description 195

Mechanism Of Action 195

R&D Progress 195

ruxolitinib phosphate-Drug Profile 197

Product Description 197

Mechanism Of Action 197

R&D Progress 197

SH-7129-Drug Profile 210

Product Description 210

Mechanism Of Action 210

R&D Progress 210

Small Molecule to Inhibit SYK for Diffuse Large B-Cell Lymphoma and Peripheral T-Cell Lymphoma-Drug Profile 211

Product Description 211

Mechanism Of Action 211

R&D Progress 211

temsirolimus-Drug Profile 212

Product Description 212

Mechanism Of Action 212

R&D Progress 212

TGR-1202-Drug Profile 214

Product Description 214

Mechanism Of Action 214

R&D Progress 214

tipifarnib-Drug Profile 221

Product Description 221

Mechanism Of Action 221

R&D Progress 221

tucidinostat-Drug Profile 224

Product Description 224

Mechanism Of Action 224

R&D Progress 224

volasertib trihydrochloride-Drug Profile 227

Product Description 227

Mechanism Of Action 227

R&D Progress 227

Peripheral T-Cell Lymphomas (PTCL)-Dormant Projects 231

Peripheral T-Cell Lymphomas (PTCL)-Discontinued Products 232

Peripheral T-Cell Lymphomas (PTCL)-Product Development Milestones 233

Featured News & Press Releases 233

Aug 16, 2016: CAR T-cells Targeting the CD4 Protein Granted FDA Orphan Drug Designation 233

Aug 11, 2016: CAR T-cells Targeting the CD4 Protein Granted Orphan Drug Designation for the Treatment of Peripheral T-cell Lymphoma 233

Jun 14, 2016: PharmaMar Announces the Start of a Pivotal Study With plitidepsin in angioimmunoblastic T-cell lymphoma 234

Jun 02, 2016: Onxeo Announces Development of Beleodaq Oral Formulation Opening New Opportunities for Its HDAC Inhibitor 234

Mar 28, 2016: Solasia Initiates Phase 2 Study of Darinaparsin (SP-02) for Peripheral T-Cell Lymphoma 235

Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan 235

Dec 07, 2015: Seattle Genetics Highlights ADCETRIS Data Presentations in Frontline Non-Hodgkin Lymphoma at ASH 2015 236

Dec 06, 2015: Spectrum Pharmaceuticals and Onxeo Announce Complete Response in 67% of Patients with Peripheral T-Cell Lymphoma in Combination of Belinostat and Standard CHOP 238

Nov 09, 2015: Onxeo Reports Initial Results of Phase 1 Trial Evaluating Belinostat in Combination with CHOP in Peripheral T-cell Lymphoma 239

Sep 30, 2015: Kura Oncology Initiates Phase 2 Study of Tipifarnib in Peripheral T-cell Lymphoma 240

Jun 23, 2015: Beleodaq (belinostat) pivotal BELIEF study results published in the Journal of Clinical Oncology 241

May 27, 2015: AB Science: Phase 2 with masitinib in peripheral T-cell lymphoma accelerated into phase 3 241

Jan 12, 2015: HUYA Bioscience International Announces Regulatory Approval Of Chidamide, The First Selective HDAC Inhibitor In China 243

Jan 09, 2015: Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China 243

Jan 08, 2015: HUYA Bioscience International Is The First To Leverage Tripartite Cooperation 244

Appendix 245

Methodology 245

Coverage 245

Secondary Research 245

Primary Research 245

Expert Panel Validation 245

Contact Us 245

Disclaimer 246

List of Figures

Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 15

Comparative Analysis by Early Stage Products, H2 2016 16

Assessment by Monotherapy Products, H2 2016 44

Number of Products by Top 10 Targets, H2 2016 45

Number of Products by Stage and Top 10 Targets, H2 2016 45

Number of Products by Top 10 Mechanism of Actions, H2 2016 48

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 48

Number of Products by Routes of Administration, H2 2016 51

Number of Products by Stage and Routes of Administration, H2 2016 51

Number of Products by Molecule Types, H2 2016 53

Number of Products by Stage and Molecule Types, H2 2016 53

List of Tables

Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Number of Products under Development by Companies, H2 2016 (Contd..1) 13

Comparative Analysis by Late Stage Development, H2 2016 14

Comparative Analysis by Clinical Stage Development, H2 2016 15

Comparative Analysis by Early Stage Development, H2 2016 16

Products under Development by Companies, H2 2016 17

Products under Development by Companies, H2 2016 (Contd..1) 18

Products under Development by Companies, H2 2016 (Contd..2) 19

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by AB Science SA, H2 2016 20

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Affimed GmbH , H2 2016 21

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by arGEN-X BV, H2 2016 22

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Bayer AG, H2 2016 23

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Boehringer Ingelheim GmbH, H2 2016 24

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Celgene Corporation, H2 2016 25

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by CerRx, Inc., H2 2016 26

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Chipscreen Biosciences Ltd, H2 2016 27

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by CSPC Pharmaceutical Group Limited, H2 2016 28

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Eisai Co., Ltd., H2 2016 29

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Genosco, H2 2016 30

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Incyte Corporation, H2 2016 31

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Japan Tobacco Inc., H2 2016 32

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Johnson & Johnson, H2 2016 33

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Mundipharma International Ltd, H2 2016 34

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 35

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Onxeo SA, H2 2016 36

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Pfizer Inc., H2 2016 37

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Pharma Mar, S.A., H2 2016 38

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Portola Pharmaceuticals, Inc., H2 2016 39

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Rhizen Pharmaceuticals S.A., H2 2016 40

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Seattle Genetics, Inc., H2 2016 41

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Solasia Pharma K.K., H2 2016 42

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016 43

Assessment by Monotherapy Products, H2 2016 44

Number of Products by Stage and Target, H2 2016 46

Number of Products by Stage and Mechanism of Action, H2 2016 49

Number of Products by Stage and Route of Administration, H2 2016 52

Number of Products by Stage and Molecule Type, H2 2016 54

Peripheral T-Cell Lymphomas (PTCL)-Dormant Projects, H2 2016 231

Peripheral T-Cell Lymphomas (PTCL)-Discontinued Products, H2 2016 232

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

AB Science SA

Affimed GmbH


Bayer AG

Boehringer Ingelheim GmbH

Celgene Corporation

CerRx, Inc.

Chipscreen Biosciences Ltd

CSPC Pharmaceutical Group Limited

Eisai Co., Ltd.


Incyte Corporation

Japan Tobacco Inc.

Johnson & Johnson

Mundipharma International Ltd

Ono Pharmaceutical Co., Ltd.

Onxeo SA

Pfizer Inc.

Pharma Mar, S.A.

Portola Pharmaceuticals, Inc.

Rhizen Pharmaceuticals S.A.

Seattle Genetics, Inc.

Solasia Pharma K.K.

Spectrum Pharmaceuticals, Inc.

Peripheral T-Cell Lymphomas (PTCL) Therapeutic Products under Development, Key Players in Peripheral T-Cell Lymphomas (PTCL) Therapeutics, Peripheral T-Cell Lymphomas (PTCL) Pipeline Overview, Peripheral T-Cell Lymphomas (PTCL) Pipeline, Peripheral T-Cell Lymphomas (PTCL) Pipeline Assessment

select a license

Single User License
USD 2000 INR 134900
Site License
USD 4000 INR 269800
Corporate User License
USD 6000 INR 404700



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]